Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma
dc.authorscopusid | 11839425100 | |
dc.authorscopusid | 57219463817 | |
dc.authorscopusid | 57204436831 | |
dc.authorscopusid | 58010281600 | |
dc.contributor.author | Köseoğlu,H. | |
dc.contributor.author | Cenkeri,H.Ç. | |
dc.contributor.author | Eroğlu,T. | |
dc.contributor.author | Yalçın,B. | |
dc.date.accessioned | 2024-05-25T12:18:19Z | |
dc.date.available | 2024-05-25T12:18:19Z | |
dc.date.issued | 2023 | |
dc.department | Okan University | en_US |
dc.department-temp | Köseoğlu H., Health Sciences University, Hamidiye Faculty of Medicine, Istanbul Health Practice and Research Center, Department of Urology, Istanbul, Turkey; Cenkeri H.Ç., Okan University, Faculty of Medicine, Department of Radiology, Turkey; Eroğlu T., Semdinli State Hospital, Department of Urology, Hakkari, Turkey; Yalçın B., Health Sciences University, Hamidiye Faculty of Medicine, Istanbul Health Practice and Research Center, Department of Radiation Oncology, Istanbul, Turkey | en_US |
dc.description.abstract | Purpose: Implementation of multiparametric magnetic resonance imaging (mpMRI) for prostate adenocarcinoma’s variant pathology requires awareness. The aim of this retrospective study was to investigate the discriminant efficacy of multiparametric magnetic resonance imaging modality for variant pathology associated with prostate adenocarcinoma. Methods: Consecutive 247 prostate cancer patients who underwent radical prostatectomy in our university-based hospital between October 2014 and October 2019, were retrospectively reviewed. Data of mpMRI-associated contrast enhancements, T2 signals, apparent diffusion coefficients (ADC), ages, and PSA values were compared. Clinical and demographic data of patients were noted including associated variant pathologies and reports of preoperative mpMRI images. Results: Among the patients, 63 (26%) had variant pathology and 14 (22%) had mpMRI before primary prostate biopsy. The group with variant pathology and the control group had similar perfusion curves and increased contrast when compared for mpMRI parameters, but different ADC values for each of the adjusted b-values for 400, 800 and 1400. Conclusion: Our study demonstrates that mpMRI appears to have no role in distinguishing rare variant pathologies associated with prostate adenocarcinoma despite different ADC values. © 2023, Urology Journal. All Rights Reserved. | en_US |
dc.identifier.citationcount | 0 | |
dc.identifier.doi | 10.22037/uj.v20i.7468 | |
dc.identifier.endpage | 161 | en_US |
dc.identifier.issn | 1735-1308 | |
dc.identifier.issue | 3 | en_US |
dc.identifier.pmid | PubMed:36840448 | |
dc.identifier.scopus | 2-s2.0-85160458849 | |
dc.identifier.scopusquality | Q3 | |
dc.identifier.startpage | 157 | en_US |
dc.identifier.uri | https://doi.org/10.22037/uj.v20i.7468 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14517/1691 | |
dc.identifier.volume | 20 | en_US |
dc.identifier.wosquality | Q4 | |
dc.language.iso | en | |
dc.publisher | Urology and Nephrology Research Centre | en_US |
dc.relation.ispartof | Urology Journal | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.scopus.citedbyCount | 0 | |
dc.subject | apparent diffusion coefficient | en_US |
dc.subject | mpMRI | en_US |
dc.subject | prostate adenocarcinoma | en_US |
dc.subject | prostate cancer variants | en_US |
dc.title | Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication |